FY2030 EPS Estimates for Gossamer Bio Cut by HC Wainwright

Gossamer Bio, Inc. (NASDAQ:GOSS) – HC Wainwright lowered their FY2030 earnings per share estimates for Gossamer Bio in a research report issued on Monday, June 1st. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of $0.09 for the year, down from their prior estimate of $0.15. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.52) per share.

Other research analysts have also issued reports about the company. Weiss Ratings lowered Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 19th. Oppenheimer lowered their price target on Gossamer Bio from $12.00 to $3.00 and set an “outperform” rating on the stock in a report on Thursday, March 5th. Wedbush reissued a “neutral” rating and set a $1.00 price target (down from $6.00) on shares of Gossamer Bio in a report on Tuesday, February 24th. Cantor Fitzgerald reissued a “neutral” rating on shares of Gossamer Bio in a report on Monday, March 23rd. Finally, The Goldman Sachs Group lowered Gossamer Bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $5.00.

Gossamer Bio Stock Performance

Shares of GOSS opened at $0.20 on Tuesday. The firm has a market capitalization of $46.49 million, a price-to-earnings ratio of -0.25 and a beta of 2.00. Gossamer Bio has a one year low of $0.16 and a one year high of $3.87. The stock’s fifty day moving average is $0.33 and its 200-day moving average is $1.66.

Gossamer Bio (NASDAQ:GOSS) last posted its earnings results on Monday, May 18th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $16.96 million during the quarter, compared to the consensus estimate of $4.67 million.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Legal & General Group Plc acquired a new position in Gossamer Bio during the second quarter worth about $26,000. Banco BTG Pactual S.A. acquired a new position in Gossamer Bio during the second quarter worth about $27,000. MMA Asset Management LLC acquired a new position in Gossamer Bio during the fourth quarter worth about $31,000. Soltis Investment Advisors LLC acquired a new position in Gossamer Bio during the fourth quarter worth about $31,000. Finally, Beacon Pointe Advisors LLC acquired a new position in Gossamer Bio during the fourth quarter worth about $34,000. 81.23% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Gossamer Bio

Here are the key news stories impacting Gossamer Bio this week:

• Negative Sentiment: Multiple law firms issued final deadline notices and class-action reminders for Gossamer Bio shareholders, keeping legal risk and potential liability in focus for the stock. Article Title
• Negative Sentiment: The lawsuit is tied to Gossamer’s February 23 announcement that its Phase 3 PROSERA study failed to meet the primary endpoint, a key clinical setback that likely contributed to the recent weakness in the shares. Article Title
• Neutral Sentiment: Additional firms, including Rosen, the Schall Law Firm, and others, continued to publicize the same case and deadline, adding to the headline overhang but not changing the underlying business picture. Article Title

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.